Introduction
The clinical diagnosis of Parkinson's disease (PD) is based on expert diagnosis applying MDS clinical diagnostic criteria (Postuma et al., 2015) . Misdiagnosis in early stages is common and a reliable molecular marker is still not available. Chemical bioelements contribute to multiple disease mechanisms in PD and might thus represent a promising alternative biomarker.
Iron, for example, has an outstanding position for PD pathogenesis: next to its well-known accumulation in the substantia nigra and other regions of the Parkinsonian brain (Dexter et al., 1989) , its interaction with a-synuclein (Uversky et al., 2001) , its involvement in ferroptotic cell death (Dixon et al., 2012) and its role as a drug target in clinical trials involving chelating agents (deferiprone in the FAIRPARK trials (Devos et al., 2014) ; www.fairpark2.eu) substantiate its importance in PD pathology. Other bioelements like selenium (Se) and the associated selenoproteins are known for their involvement in the oxidative stress response (Ellwanger et al., 2016) and for their dysregulation in the post-mortem Parkinsonian brain (Bellinger et al., 2012 (Bellinger et al., , 2011 Boukhzar et al., 2016) . Arsenic (As), magnesium (Mg), strontium (Sr) and nickel (Ni) were also implicated in PD pathogenesis based on data from epidemiological studies and different PD models (Cholanians et al., 2016; Slotkin and Seidler, 2011; Sun, 2018) . In PD mimics like dementia with Lewy bodies or normal pressure hydrocephalus (NPH), different bioelements and metal-binding protein were also discussed to function as potential biomarkers (Boström et al., 2009; Murakami et al., 2018) .
J o u r n a l P r e -p r o o f 6 Based on the results of our monocentric exploratory cohort on bioelements in the CSF of patients with PD and age-matched control subjects (AMC) (Maass et al., 2018) , we now validated the discriminative power of a predictive machine learning model based on the abundance of six bioelements in the CSF (As, Se, Fe, Mg, Ni, Sr), defined within the exploratory cohort. For the exploratory discovery cohort, we initially quantified 19 different bioelements and used machine learning for prediction of PD and AMC. Thereafter, we reduced the number of elements needed for predictive modeling by applying a stepwise removal of the least informative element, finally presenting a discriminative minimum cluster of the six bioelements, as mentioned above. We hypothesized that using predictive models based on elemental patterns instead of the levels of individual single bioelement, might increase the robustness as a biomarker.
Here, we present the results of the validation of our discovery cohort in four independent cohorts. In addition to an independent validation cohort from our own center (C1), we analyzed the accuracy of prediction in an external clinically matched cohort of similar size (C2), as well as two additional smaller cohorts with different patient characteristics (C3 and C4), also including NPH patients as a frequent differential diagnosis of PD. A Support Vector Machines (SVM) model, based on the bioelemental abundance quantified in the discovery cohort, was used for the discrimination of PD patients and AMC, allowing us to provide class II level of evidence for the potential discriminative power of bioelements in PD.
Material and methods
J o u r n a l P r e -p r o o f 9 Element determination (As, Fe, Mg, Ni, Se, Sr) was performed as described before (Maass et al., 2018) . In brief, an inductively coupled plasma-optical emission spectrometry (ICP-OES) system was used for element determination and an inductively coupled plasma-sector field-mass spectrometry (ICP-sf-MS) instrument was employed for determination of elements, which were below the limit of quantification from ICP-OES (technical details are given in the supplement).
Statistical analysis
Quantitative data of two groups was compared using either t test or Mann-Whitney U test, as appropriate. Qualitative data was compared using chi-squared test. Multiple groups were compared using either one-way or two-way ANOVA with Tukey's multiple comparisons test.
Element levels were log-10 transformed and values below the limit of quantification were imputed using model-based robust expectation-maximization for left-censored data (Helsel, 2005; Palarea-Albaladejo and Martín-Fernández, 2015) . Principal component analysis (PCA) of scaled data was used to visualize potential clusters. A scree plot was used for the visualizing of the explained variance of the different components. A radial kernel Support Vector Machine (SVM) algorithm was trained on preprocessed (centered, scaled) CSF levels of As, Fe, Mg, Ni, Se, Sr of a recent discovery cohort (Maass et al., 2018) using 10 times 10fold cross validation for hyperparameter tuning and after that applied to predict PD and AMC / NPH of the different centers (cohort C1-C4) of the validation cohort. The resulting estimates for the area under the receiver operating characteristic (ROC) curve were visualized. The same SVM algorithm was again trained and tested on each center of the validation cohort separately, using 10 times 10-fold cross validation (C1, C2) or leave-one-out cross validation (LOOCV) (C3, C4), for the definition of center-specific discovery cohorts. The performance was again visualized using ROC curves. Correlation between element levels and clinical parameter was performed using Spearman correlation after adjusting for multiple testing according to Bonferroni. Correlation between Fe and disease duration was controlled for age Journal Pre-proof J o u r n a l P r e -p r o o f given in the supplement) were used for data analysis.
Results

Participants characteristics
A total of 157 patients (82 PD, 68 AMC and 7 NPH) were recruited in four different neurological centers (cohort C1-C4). Within each cohort, there were no significant age or sex differences between the PD and AMC or NPH group, respectively (p > 0.05). Demographical and clinical characteristics of the study population are given in Table 1 .
Cohort 1 and cohort 2 represent clinically matched validation cohorts (cohort 1: independent local validation cohort; cohort 2: external validation cohort) without differences in age, H&Y stage, disease duration or UPDRS III score (p > 0.05). Inter-cohort comparison of the clinical characteristics can be found in Supplementary Table S1 . Cohort 3 and cohort 4 represent two additional smaller cohorts with different patient characteristics (cohort 3: PD patients with a shorter disease duration; cohort 4: patients with NPH instead of AMC). 
CSF baseline element levels and center effects
To validate a set of six differentiating elements in the CSF (As, Fe, Mg, Ni, Se, Sr; as described in (Maass et al., 2018) ), we quantified the abundance of the same six elements in the current study. 
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Comparing the elemental levels between PD and AMC in each cohort (cohort C1-C4) respectively, we found significant differences in individual cohorts, which, however, were never reproduced in the other cohorts (visualized in Figure 1 , summarized in Supplementary   Table S2 ). Inter-cohort comparisons of bioelement levels within the PD and the AMC group respectively, revealed multiple significant differences in the levels of As, Ni, Se and Sr, while levels of Fe and Mg showed a relatively stable abundance ( Supplementary Table S3 ).
J o u r n a l P r e -p r o o f As suggested by the inter-cohort comparison, the principal component analysis (PCA) reveals multiple center effects (Supplementary Figure S1 ).
Classification of PD and AMC / NPH patients by Support Vector Machines
In order to classify PD and AMC/NPH patients, a non-linear SVM model was trained on the CSF abundance of the same six elements (As, Se, Fe, Mg, Sr, Ni) that were quantified in our recent discovery cohort (36 PD and 42 AMC, as described in (Maass et al., 2018) ). The characteristics of the discovery cohort can be found in the supplement ( Supplementary Table   S4 and S5). This predefined model was used to classify PD and AMC or NPH patients of a new local cohort (C1, same center as in the discovery cohort) and three external cohorts (C2-C4).
Using the predefined SVM model, we were able to classify PD and AMC patients of the new local validation cohort (cohort 1, Figure 2A) with an AUROC of 0.76 (Sensitivity 0.80, Specificity 0.83 at Youden index) purely based on the abundance of those six elements without taking any additional features into account. Adding age and CSF albumin concentration, increased the accuracy further (AUROC 0.79, Sensitivity 0.83, Specificity 0.83 and AUROC 0.82, Sensitivity 0.77, Specificity 0.86 at Youden index, respectively; Figure 2B and C). This model, however, was not able to discriminate the patients of cohort 2 (clinical matched, external cohort, AUROC 0.57, Figure 2D ) and cohort 3 (external cohort with different characteristics, AUROC 0.52, Figure 2E ). A discrimination of PD and NPH patients in cohort 4 was similarly not feasible using this model (AUROC 0.51, Figure 2F ). 
Evaluation of new center specific models using SVM
The inability of the SVM trained on the discovery cohort to correctly classify patients from cohorts 2 to 4 could be either due to a general lack of information in the elemental data set or derived by a particular center bias. If the six elements were to lack the classifying information, SVM applied to each cohort independently would not be able to separate PD from AMC/NPH patients. On the other hand, there could exist a specific center bias, which would require a center-specific training cohort for each single center. To answer this J o u r n a l P r e -p r o o f approach (C1, C2) or a leave-one-out cross validation (C3, C4), the SVM algorithm was indeed able to discriminate PD and AMC patients in cohort 1 and 2 ( Figure 3A and 3B, AUROC 0.76 and 0.78), and PD and NPH patients in cohort 4 ( Figure 3D , AUROC 0.88).
The algorithm failed, however, to build a functional model for cohort 3 (Figure 3C , AUROC 0.31), where only four (Fe, Se, As, Ni) of the initially six determined elements could be quantified due to limited sample volume. 
Correlation with the clinical data
To determine if elemental abundance correlates with clinical parameters (age, H&Y stage, UPDRS part III, disease duration, MoCA, LED), spearman correlation analysis was applied.
PD patients of all cohorts were pooled for this analysis. After Bonferroni correction (adjusted alpha ≤ 0.0014), there were significant correlations between Mg and the LED (p=0.0013, Supplementary Figure S2 ) and more importantly between iron and disease duration (p=0.0001, Figure 4 ). Multiple linear regression was applied to control this relationship for age, still showing a significant relationship (p = 0.0018). 
Environmental influences on bioelemental CSF concentrations: soil and groundwater concentrations
Bioelements are taken up in the brain and CSF by various mechanisms and partially depend on their environmental supply. Therefore, we investigated whether levels of these six elements in soil or groundwater correlated with the levels detected in our CSF samples.
Environmental concentrations of As, Fe, Mg, Ni, Se, and Sr in top soil and ground water for the geographical regions of the four cohorts (within 50 km range), were provided by the Federal Institute for Geosciences and Natural Resources, Hannover, Germany (Supplementary Figure S3 ).
J o u r n a l P r e -p r o o f
Discussion
Here we present the first multicentric trial on the accuracy of an elemental signature in CSF to differentiate patients with PD and control subjects. In contrast to previously published, mainly monocentric exploratory analyses without further validation (e.g. trials on CSF iron levels (Alimonti et al., 2007; Forte et al., 2004; Gazzaniga et al., 1992; Hozumi et al., 2011; Jiménez-Jiménez et al., 1998; Pall et al., 1987; Sanyal et al., 2016; Willkommen et al., 2018) , our data relies on CSF samples from four independent cohorts, including patients with different disease durations and NPH as a frequently encountered PD mimic. Employing an SVM model, we were able to validate the elemental profile in the local part of the validation cohort but not in the external cohorts. However, applying independent center specific SVM models for the differentiation of PD and controls demonstrated discriminative value of the elemental profile in two out of three external cohorts.
Bioelements have many advantages as compared to other biomarker molecules, e.g.
proteins, RNA or metabolites: chemical elements as such are not affected from degradation and they remain stable at low and moderate temperature (only at critically elevated temperature volatile elements such as iodine, mercury may be affected: this does not apply to herein investigated elements), pH or sampling-analysis delay (Bornhorst et al., 2005; Tevis et al., 2018; Wiberg et al., 2001) . Moreover, a number of individual elements have been attributed particular roles in the pathogenesis of PD (e.g. iron, copper, manganese) (Davies et al., 2014; Dexter et al., 1989; Mortimer et al., 2012) .
To obtain an elemental fingerprint by a combination of six pre-defined elements, we used the Support Vector Machines (SVM) algorithm: it was previously successfully used for discrimination of patients with PD and Multiple System Atrophy based on proteomics data (Mattison et al., 2012) , it was efficient in multicenter settings (Lindemer et al., 2018) and it is able to tolerate high noise levels in training data (Kumar et al., 2011) .
J o u r n a l P r e -p r o o f
Applying SVM to the local validation cohort (C1) demonstrates the plausibility of the proposed model with an AUROC of 0.76 for the discrimination of PD and AMC, purely based on the abundance of As, Fe, Mg, Ni, Se and Sr. Although we observed a significant decrease in Se levels in the PD group, this was not the case in other cohorts (C2-C4). This is consistent with our hypothesis that the abundance of individual elements alone lacks predictive power, because multiple exogenous and endogenous factors influence their abundance and result in fluctuating levels depending on the context (Jiménez-Jiménez et al., 2014; Mariani et al., 2013) . The combination of elements, however, may provide a more robust signature considering their interactions and thus is more suited as a biomarker.
Adding additional characteristics to the model (age and CSF albumin) resulted in a moderate increase in discriminative power, resulting in an AUROC of 0.82 for the local cohort. Both parameters were included based on their potential availability in the clinical routine, so they could be easily integrated into the model in a translational approach. Whereas age is a wellknown independent risk factor for PD (Hindle, 2010) , increased CSF albumin levels reflect blood-brain-barrier dysfunction, which has been observed in different neurodegenerative J o u r n a l P r e -p r o o f step-wise removal of the least informative elements-procedure in the initial discovery cohort (Maass et al., 2018) .
The successful establishment of a center specific functional model based on the data from validation cohorts C2 and C4, but not from the original discovery cohort argues in favor of a substantial center bias, which is also suggested by center-dominated clustering in the PCA.
Such center biases have been described for different biomarkers and can be attributed to 1) differences in pre-analytical or analytical factors, 2) differences in patient characteristics or medication and 3) differences in environmental factors and diet (Lewczuk et al., 2018; Mattsson et al., 2010; Mollenhauer et al., 2015) .
Even though sample collection was done according to standardized biomarker protocols (Teunissen et al., 2009) , center differences in sample processing, collected CSF fractions and their corresponding ventricular/lumbar gradient, minor blood contaminations with subsequent release of serum derived elements, different equipment (with unknown potential of element interaction) and in particular the clinical heterogeneity in health status of the control groups might influence elemental levels. Standardized biomarker protocols applying more rigorously standards compared to protein research might be needed to reduce these influential factors. As all mass spectrometry analyses were performed simultaneously at one analytical facility, including internal and external standards, we can largely exclude that the analysis method contributes to the observed variability.
Regarding clinical characteristics, we did not observe significant differences in age, disease duration, Hoehn & Yahr stage, UPDRS III-or MoCA scores between the local validation cohort C1 and the clinical matched cohort C2, which together represent 85% of all analyzed patients in this study. The only significant correlation between the levodopa equivalent dose (LED) and elemental abundance was observed for magnesium, but the clinical relevance of this finding remains elusive (Supplementary Figure S2) . Interestingly, we found a significant correlation between iron levels and disease duration, even if controlled for age. Progressive iron deposition has been described in the substantia nigra of PD patients (Dexter et al., J o u r n a l P r e -p r o o f 1989) and our analysis shows for the first time, to the best of our knowledge, correlation of iron CSF levels with disease duration. Non-Parkinsonian factors like concomitant diseases or general drug intake might affect CSF levels by influencing blood-brain-CSF equilibria, but larger cohort sizes would be needed to robustly analyze these diverse factors.
Environmental factors are suspected to account for the main part of center variability and have been previously shown to correlate with clinical parameters. For example, a recent epidemiological study linked Se, Sr and Mg concentrations in top soil to PD mortality rates (Sun, 2018) . These and other elements that are present in our environment (e.g. in drinking water, food, soil, dust) can be incorporated and affect element levels in different tissues (also see www.atsdr.cdc.gov). Uptake, storage and release of numerous elements (e.g. iron or manganese) is tightly regulated in the CNS (Bowman et al., 2011; Mills et al., 2010; Nischwitz et al., 2008) . Selenium and iron, reflecting two important factors in our model, are rather robust to changes in serum levels e.g. by dietary habits due to the regulation of their intake via the blood-brain-barrier. Selenium shows total CSF levels which are largely independent of its serum levels and this is also true for the most important selenoprotein SEPP1 (Solovyev et al., 2013) . Similarly, brain iron levels are not easily altered with diet, particularly in adults (in contrast to the critical time point of weaning (Hare et al., 2013) ).
Concentrations of other elements, however, largely depend on their environmental abundance and nutritional supply (e.g., magnesium or arsenic) (Morris, 1992; Nischwitz et al., 2008; Yang et al., 2012) . For example, arsenic in the form of arsenate resembles nutrient phosphate and is taken up by phosphate transport systems . Thus, dietary habits might confound with elemental levels but cannot explain group differences on their own. We obtained elemental concentrations from soil and ground water for the geographical regions of the four cohorts (within 50 km range), which did not demonstrate a significant correlation with the respective CSF levels. Most likely, the number of centers and patients in our study did not yield sufficient power to detect environmental influences (Sun, 2018) .
Furthermore, intake by air and food are also potentially influencing factors, which were not considered. It is also likely that a substantial number of patients do not live in the 50 km-radius of the centers, due to referral from more distant areas. Additionally, individual relocation-, travel and exposure history might confound our data.
In 
